Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Globe Newswire (Fri, 10-May 4:00 PM ET)
TipRanks (Wed, 8-May 9:21 AM ET)
Esperion Gains Buy Rating on Strong Sales Growth and Strategic Progress
TipRanks (Wed, 8-May 6:25 AM ET)
TipRanks (Wed, 8-May 5:32 AM ET)
Esperion’s Market Uncertainty Justifies Hold Rating Despite Promising Early Results
TipRanks (Wed, 8-May 5:30 AM ET)
Analysts’ Top Healthcare Picks: Esperion (ESPR), Beam Therapeutics (BEAM)
TipRanks (Tue, 7-May 1:30 PM ET)
Analysts Offer Insights on Healthcare Companies: Esperion (ESPR) and Beam Therapeutics (BEAM)
TipRanks (Tue, 7-May 1:20 PM ET)
Analysts Offer Insights on Healthcare Companies: Esperion (ESPR) and Travere Therapeutics (TVTX)
TipRanks (Tue, 7-May 12:30 PM ET)
Esperion Therapeutics beats top-line and bottom-line estimates; reaffirms FY24 outlook
Seeking Alpha News (Tue, 7-May 6:04 AM ET)
Esperion Reports First Quarter 2024 Financial Results
Globe Newswire (Tue, 7-May 6:00 AM ET)
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
Esperion Therapeutics trades on the NASDAQ stock market under the symbol ESPR.
As of May 10, 2024, ESPR stock price climbed to $2.19 with 8,964,063 million shares trading.
ESPR has a beta of 4.09, meaning it tends to be more sensitive to market movements. ESPR has a correlation of 0.21 to the broad based SPY ETF.
ESPR has a market cap of $405.27 million. This is considered a Small Cap stock.
Last quarter Esperion Therapeutics reported $138 million in Revenue and $.34 earnings per share. This beat revenue expectation by $53 million and exceeded earnings estimates by $.29.
In the last 3 years, ESPR stock traded as high as $26.77 and as low as $.70.
The top ETF exchange traded funds that ESPR belongs to (by Net Assets): VTI, VXF, ITOT, IWC, JFWD.
ESPR has outperformed the market in the last year with a price return of +54.2% while the SPY ETF gained +28.4%. However, in the short term, ESPR had mixed performance relative to the market. It has underperformed in the last 3 months, returning -15.1% vs +4.2% return in SPY. But in the last 2 weeks, ESPR shares have fared better than the market returning +10.1% compared to SPY +3.4%.
ESPR support price is $1.97 and resistance is $2.22 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ESPR stock will trade within this expected range on the day.